WTX212A(WTX212A) - 在研适应症：肺癌_专利_临床

概要

基本信息

药物类型

未知

别名

靶点-

作用机制-

治疗领域

肿瘤呼吸系统疾病

在研适应症

肺癌

非在研适应症-

原研机构

西湖生物医药科技（杭州）有限公司

在研机构

西湖生物医药科技（杭州）有限公司

非在研机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)早期临床1期

特殊审评-

登录后查看时间轴

关联

2

项与 WTX212A 相关的临床试验

NCT06106152 / Recruiting早期临床1期IIT

A Single-center, Open Label, Exploratory Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of WTX212A Injection Combined With PD -1/PD-L1 Monoclonal Antibody in Patients With Advanced Lung Cancer

This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD -1/PD-L1 monoclonal antibody in patients with advanced lung cancer

开始日期2023-12-05

申办/合作机构

浙江大学医学院附属第二医院

[+1]

NCT06026605 / Recruiting早期临床1期IIT

A MulticenterOpen LableDose Escalat Tion and Dose Expansion Clinical Study to Evaluate the Safety, Tolerance and Ini Itial Effectiveness of WTX212A Injection in Patients With Unresectable or Metasta Atic Advanced Solid Tumors

This trial is a multi-center, open-label investigator-initiated clinical study (IIT) to evaluate the safety, pharmacokinetics, pharmacodynamics and effectiveness of WTX212A injection in the treatment of patients with unresectable or metastatic advanced solid tumors who failed in previous systematic therapy.
The study was divided into two phases: dose escalation and dose expansion

开始日期2023-08-25

申办/合作机构